BRPI0511889A - therapeutic reprogramming, hybrid stem cells and maturation - Google Patents

therapeutic reprogramming, hybrid stem cells and maturation

Info

Publication number
BRPI0511889A
BRPI0511889A BRPI0511889-1A BRPI0511889A BRPI0511889A BR PI0511889 A BRPI0511889 A BR PI0511889A BR PI0511889 A BRPI0511889 A BR PI0511889A BR PI0511889 A BRPI0511889 A BR PI0511889A
Authority
BR
Brazil
Prior art keywords
cells
stem cells
maturation
therapeutic reprogramming
therapeutically
Prior art date
Application number
BRPI0511889-1A
Other languages
Portuguese (pt)
Inventor
Chauncey B Sayre
Francisco J Silva
Original Assignee
Primegen Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/864,788 external-priority patent/US20050090004A1/en
Application filed by Primegen Biotech Llc filed Critical Primegen Biotech Llc
Publication of BRPI0511889A publication Critical patent/BRPI0511889A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/061—Sperm cells, spermatogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REPROGRAMAçãO TERAPêUTICA, CéLULAS-TRONCO HìBRIDAS E MATURAçãO São providas células programadas terapeuticamente e métodos para fazer tais células. Células programadas terapeuticamente são células-tronco que foram maturadas tal que elas representam um estado mais diferenciado ou um estado menos diferenciado após o contato com fatores estimulatórios. As células reprogramadas terapeuticamente são adequadas para terapia regenerativa celular e têm o potencial de se diferenciar em linhagens celulares mais comprometidas. Adicionalmente, são providas células-tronco híbridas adequadas para reprogramação terapêutica e terapia regenerativa celular.THERAPEUTIC REPROGRAMMING, HYBRID BODY CELLS AND MATURATION Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells that have been matured such that they represent a more differentiated state or a less differentiated state following contact with stimulatory factors. Therapeutically reprogrammed cells are suitable for cell regenerative therapy and have the potential to differentiate into more compromised cell lines. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cell regenerative therapy are provided.

BRPI0511889-1A 2004-06-08 2005-02-16 therapeutic reprogramming, hybrid stem cells and maturation BRPI0511889A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/864,788 US20050090004A1 (en) 2003-01-16 2004-06-08 Stem cell maturation for all tissue lines
US58814604P 2004-07-15 2004-07-15
PCT/US2005/005052 WO2005123123A2 (en) 2004-06-08 2005-02-16 Therapeutic reprogramming, hybrid stem cells and maturation

Publications (1)

Publication Number Publication Date
BRPI0511889A true BRPI0511889A (en) 2008-01-15

Family

ID=35355246

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511889-1A BRPI0511889A (en) 2004-06-08 2005-02-16 therapeutic reprogramming, hybrid stem cells and maturation

Country Status (7)

Country Link
EP (1) EP1758989A2 (en)
JP (1) JP2008501795A (en)
AU (1) AU2005253923A1 (en)
BR (1) BRPI0511889A (en)
CA (1) CA2567692A1 (en)
RU (1) RU2006147263A (en)
WO (1) WO2005123123A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622231B (en) 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
EP2796873A1 (en) * 2013-04-25 2014-10-29 QGel SA Method for a cell-based drug screening assay and the use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69937888T2 (en) * 1998-07-31 2009-01-02 Genzyme Corp., Cambridge Process for the preparation of mesenchymal stem cells
US20020136709A1 (en) * 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
JP2004248505A (en) * 2001-09-21 2004-09-09 Norio Nakatsuji Undifferentiated fusion cell of somatic cell derived from es cell deficient in part or all of transplantation antigen and method for producing the same
EP1468088A4 (en) * 2002-01-16 2006-02-15 Primegen Biotech Llc Stem cell maturation for all tissue types
CA2484629A1 (en) * 2002-05-31 2003-12-11 Apollo Life Sciences Pty Limited Electrofusion of cells and apparatus therefore
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells

Also Published As

Publication number Publication date
WO2005123123A3 (en) 2006-03-02
RU2006147263A (en) 2008-07-20
WO2005123123A2 (en) 2005-12-29
AU2005253923A1 (en) 2005-12-29
CA2567692A1 (en) 2005-12-29
EP1758989A2 (en) 2007-03-07
JP2008501795A (en) 2008-01-24

Similar Documents

Publication Publication Date Title
NZ598176A (en) Disintegrin variants and pharmaceutical uses thereof
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
MX2009005849A (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna.
MX2009004238A (en) Methods and compositions for treatment of bone defects with placental cell populations.
TW200736260A (en) Inhibitors of Akt activity
AU2003285172A8 (en) Human embryonic stem cell cultures, and compositions and methods for growing same
IL179919A0 (en) Neural stem cells, compositions containing the same and methods for promoting the division thereof
BRPI0507812A (en) microactivation system, method for epidermal cell microactivation, kit, method for mounting the microactivation device and method for skin microactivation
MX2007015217A (en) Automated cell therapy system.
AU2003303384A8 (en) Uses of mammalian cytokine; related reagents
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
MX2009009225A (en) Definitive endoderm.
MXPA05009694A (en) Methods of improving skin quality.
ATE514772T1 (en) MULTIPOTENT ADULT STEM CELLS AND METHOD FOR ISOLATION THEREOF
MX2018012512A (en) Placental stem cell populations.
TW200716110A (en) Inhibitors of AKT activity
IL173369A0 (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
SI1941027T1 (en) Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics.
MX2007008980A (en) Nucleic acids for apoptosis of cancer cells.
MX2007000418A (en) Methods and reagents for treating honeybees for parasitic mites.
BRPI0511889A (en) therapeutic reprogramming, hybrid stem cells and maturation
EP1536500A4 (en) Electrode for fuel cell, fuel cell including the electrode and process for producing the same
TW200722090A (en) Compounds useful for inhibiting chk1
AU2002303437A1 (en) Isolation of neural stem cells using gangliosides and other surface markers

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.